(VIANEWS) – MULTICONSULT (MULTI.OL), INCLUSIO SA/NV (INCLU.BR), TOTALENERGIES (TTE.PA) have the highest dividend yield stocks on this list.
| Financial Asset | Forward Dividend Yield | Updated (EST) |
|---|---|---|
| MULTICONSULT (MULTI.OL) | 7.5% | 2023-12-04 08:41:13 |
| INCLUSIO SA/NV (INCLU.BR) | 5.47% | 2023-12-03 07:15:09 |
| TOTALENERGIES (TTE.PA) | 4.7% | 2023-12-04 09:23:54 |
| INNATE PHARMA (IPH.PA) | 4.64% | 2023-12-04 09:06:10 |
| SQLI (SQI.PA) | 3.04% | 2023-12-03 08:01:14 |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. MULTICONSULT (MULTI.OL)
7.5% Foward Dividend Yield
MULTICONSULT’s last close was kr120.00, 28.99% under its 52-week high of kr169.00. Intraday change was 1.25%.
Multiconsult ASA provides engineering design, consultancy, and architecture services in Norway and internationally. The company offers multidisciplinary consultancy, design, planning, project supervision and management, geotechnical site survey, verification and control, analysis and due diligence, construction management, geological investigations, environmental services and HSE, river basin management, hydrometry, and hydrological field work services. It serves buildings and properties, cities and society, industry, oil and gas, renewable energy, rail and transportation, and water and environment sectors. Multiconsult ASA was founded in 1908 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MULTICONSULT has a trailing twelve months EPS of kr10.22.
PE Ratio
MULTICONSULT has a trailing twelve months price to earnings ratio of 11.89. Meaning, the purchaser of the share is investing kr11.89 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.75%.
Volatility
MULTICONSULT’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.71%, a negative 0.13%, and a positive 1.24%.
MULTICONSULT’s highest amplitude of average volatility was 1.27% (last week), 0.92% (last month), and 1.24% (last quarter).
More news about MULTICONSULT.
2. INCLUSIO SA/NV (INCLU.BR)
5.47% Foward Dividend Yield
INCLUSIO SA/NV’s last close was €13.60, 15% below its 52-week high of €16.00. Intraday change was 1.87%.
Inclusio SA operates as a real estate company in Belgium. It focuses on affordable rental housing, housing for disabled, and social infrastructures. Inclusio SA was incorporated in 2011 and is based in Brussels, Belgium.
Earnings Per Share
As for profitability, INCLUSIO SA/NV has a trailing twelve months EPS of €2.37.
PE Ratio
INCLUSIO SA/NV has a trailing twelve months price to earnings ratio of 5.74. Meaning, the purchaser of the share is investing €5.74 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.65%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 24.2%, now sitting on 12.4M for the twelve trailing months.
Volume
Today’s last reported volume for INCLUSIO SA/NV is 951 which is 51.35% below its average volume of 1955.
More news about INCLUSIO SA/NV.
3. TOTALENERGIES (TTE.PA)
4.7% Foward Dividend Yield
TOTALENERGIES’s last close was €62.36, 3.39% under its 52-week high of €64.55. Intraday change was -1.96%.
TotalEnergies SE, a multi-energy company, produces and markets fuels, natural gas, and electricity in France, rest of Europe, North America, Africa, and internationally. It operates through Integrated Gas, Renewables & Power; Exploration & Production; Refining & Chemicals; and Marketing & Services segments. The Integrated Gas, Renewables & Power segment engages in integrated gas, including liquified natural gas (LNG), and low carbon electricity businesses; and upstream and midstream LNG activities. Its Exploration & Production segment offers carbon storage and nature-based solutions. The Refining & Chemicals segment provides refining, petrochemicals, and specialty chemicals; and supply and trading of oil, and marine shipping services. Its Marketing & Services segment engages in the supply and marketing of petroleum products. TotalEnergies SE was formerly known as TOTAL SE and changed its name to TotalEnergies SE in June 2021. The company was founded in 1924 and is headquartered in Courbevoie, France.
Earnings Per Share
As for profitability, TOTALENERGIES has a trailing twelve months EPS of €7.21.
PE Ratio
TOTALENERGIES has a trailing twelve months price to earnings ratio of 8.48. Meaning, the purchaser of the share is investing €8.48 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.66%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 16.2%, now sitting on 228.13B for the twelve trailing months.
Yearly Top and Bottom Value
TOTALENERGIES’s stock is valued at €61.14 at 16:50 EST, under its 52-week high of €64.55 and way above its 52-week low of €50.55.
More news about TOTALENERGIES.
4. INNATE PHARMA (IPH.PA)
4.64% Foward Dividend Yield
INNATE PHARMA’s last close was €2.26, 40.66% under its 52-week high of €3.80. Intraday change was 1.55%.
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Earnings Per Share
As for profitability, INNATE PHARMA has a trailing twelve months EPS of €-0.79.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -71.91%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, INNATE PHARMA’s stock is considered to be overbought (>=80).
Volatility
INNATE PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.33%, a negative 0.26%, and a positive 2.47%.
INNATE PHARMA’s highest amplitude of average volatility was 2.52% (last week), 2.00% (last month), and 2.47% (last quarter).
Volume
Today’s last reported volume for INNATE PHARMA is 31008 which is 70.21% below its average volume of 104117.
More news about INNATE PHARMA.
5. SQLI (SQI.PA)
3.04% Foward Dividend Yield
SQLI’s last close was €42.40, 16.86% under its 52-week high of €51.00. Intraday change was 0%.
SQLI SA engages in digital experience and unified commerce businesses in France and internationally. The company provides e-commerce strategy and acceleration, solution design and technology architecture, product information management, marketplace, digital store, and e-commerce marketing services; web design and development, digital workplace, mobile development, website performance, custom applications and configuration solutions for experience platforms; and technology and transformation solutions, including custom applications, outsourced service centers, multi-technology, enterprise architecture, application management and hosting, and agile and lean. It also offers business intelligence/data visualization, data modernization/move to cloud, MDM/PIM, analytics, data science, big data, and unified customer data solutions; digital marketing and design services comprising customer journey and user experience, social media marketing, content and motion design, and design sprint services; and digital consulting services, such as digital strategy and roadmap, audit and scoping, digital responsibility, digital marketing strategy, and experience and change management. SQLI SA was incorporated in 1990 and is headquartered in Levallois-Perret, France.
Earnings Per Share
As for profitability, SQLI has a trailing twelve months EPS of €1.78.
PE Ratio
SQLI has a trailing twelve months price to earnings ratio of 23.82. Meaning, the purchaser of the share is investing €23.82 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.63%.
Yearly Top and Bottom Value
SQLI’s stock is valued at €42.40 at 16:50 EST, way below its 52-week high of €51.00 and way higher than its 52-week low of €36.10.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jul 21, 2017, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 3.04%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3%, now sitting on 249.6M for the twelve trailing months.
More news about SQLI.
